Alternative dosing regimens for atezolizumab: right dose, wrong frequency

Daniel A. Goldstein; Mark J. Ratain

doi:10.1007/s00280-019-03971-7

Alternative dosing regimens for atezolizumab: right dose, wrong frequency

Daniel A. Goldstein, Mark J. Ratain^*

^*Corresponding author for this work

Oncology

Research output: Contribution to journal › Editorial

22 Scopus citations

Abstract

The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.

Original language	English
Pages (from-to)	1153-1155
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	84
Issue number	6
DOIs	https://doi.org/10.1007/s00280-019-03971-7
State	Published - 1 Dec 2019

Keywords

Atezolizumab
Pharmacoeconomics
Pharmacokinetics
Schedule

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-019-03971-7

Cite this

@article{acf0c8bd9bce4b7d8a28032fd535cd55,

title = "Alternative dosing regimens for atezolizumab: right dose, wrong frequency",

abstract = "The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.",

keywords = "Atezolizumab, Pharmacoeconomics, Pharmacokinetics, Schedule",

author = "Goldstein, \{Daniel A.\} and Ratain, \{Mark J.\}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s00280-019-03971-7",

language = "אנגלית",

volume = "84",

pages = "1153--1155",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

TY - JOUR

T1 - Alternative dosing regimens for atezolizumab

T2 - right dose, wrong frequency

AU - Goldstein, Daniel A.

AU - Ratain, Mark J.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.

AB - The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.

KW - Atezolizumab

KW - Pharmacoeconomics

KW - Pharmacokinetics

KW - Schedule

UR - https://www.scopus.com/pages/publications/85074136647

U2 - 10.1007/s00280-019-03971-7

DO - 10.1007/s00280-019-03971-7

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 31630223

AN - SCOPUS:85074136647

SN - 0344-5704

VL - 84

SP - 1153

EP - 1155

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 6

ER -

Alternative dosing regimens for atezolizumab: right dose, wrong frequency

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this